Peter E. Fecci

Jan 14, 2025 | sciencedirect.com | M.B. El Mdawar |Jessica Waibl Polania |Peter E. Fecci |Deguan Lv

Glioblastoma, the most common primary tumor of the central nervous system (CNS), remain uniformly aggressive and lethal, with a median survival of less than 2 years.1,2,3,4 Glioblastoma stem cells (GSCs) possess the fundamental stem cell properties including self-renewal, multi-potency, and tumor maintenance, and they share other characteristics with normal neural stem cells (NSCs).5,6 Although they comprise a small fraction of total tumor cells, GSCs have been demonstrated to promote tumor...

Jan 14, 2025 | sciencedirect.com | Wenbin Mei |Sohail F. Tavazoie |Jessica Waibl Polania |Peter E. Fecci

Immune checkpoint blockade (ICB) therapies have improved the outcome of patients with malignant tumors. However, most cancer patients barely benefit from ICB treatments.1 Deciphering mechanisms for ICB resistance, especially cancer cell-intrinsic factors mediating immune escape, will improve ICB efficacy.

Dec 25, 2024 | cell.com | Jessica Waibl Polania |Alexandra M Hoyt-Miggelbrink |William H. Tomaszewski |Lucas P Wachsmuth |Selena J. Lorrey |Daniel Wilkinson | +5 more

Keywords T cell exhaustion tumor-associated macrophage tumor microenvironment tumor immunology immunotherapy brain tumor brain metastasis glioblastoma Introduction Brain tumors, both primary and metastatic, continue to herald poor survival.1,2 Immunotherapies, such as immune checkpoint blockade (ICB) and chimeric antigen receptor (CAR) T cells, hold promise for improving outcomes but remain only marginally effective within the intracranial confines.3,4 This has been especially true in the...

Jul 24, 2023 | nature.com | Ian F. Parney |Solmaz Sahebjam |Nader Sanai |Michael Platten |Michael Lim |Timothy F. Cloughesy | +11 more

A breakthrough in drug discovery for glioblastoma requires serial collection of tissue from the central nervous system via window of opportunity trials Therapeutic drug development in glioblastoma has remained static despite numerous clinical trials, advances in tumor biology, and substantial public interest. Since 2005, more than 1,250 interventional glioblastoma trials have been registered on ClinicalTrials.gov.